-transparent.png){kind=logo}
In the present study, we aimed to investigate whether EGFR or HER2 may serve as a target for T cell-mediated immunotherapy against human bladder cancer. Expression of EGFR and HER2 was detected on the surface of bladder cancer cells, including Pumc-91 and T24 cells, and their chemotherapeutic drug-resistant counterparts. Activated T cells (ATCs) were generated from healthy PBMCs that were stimulated by the combination of anti-CD3 monoclonal antibody and anti‑CD28 monoclonal antibody in the presence of interleukin-2 for 14 days. The ATCs were then armed with chemically hetero-conjugated anti-CD3xanti-EGFR (EGFRBi-Ab) or anti-CD3xanti-HER2 (HER2Bi-Ab). The specific cytolytic activity of ATCs armed with EGFRBi-Ab or HER2Bi-Ab against human bladder cancer cells was evaluated by lactate dehydrogenase activity assays in vitro. In contrast to unarmed ATCs, EGFRBi-Ab-armed ATCs and HER2Bi-Ab-armed ATCs showed increased cytotoxic activity against bladder cancer cells. Moreover, Bi-Ab-armed ATCs expressed higher levels of activating marker CD69 and secreted more IFN-γ, TNF-α and IL-2 than did unarmed ATCs. EGFRBi-Ab- or HER2Bi-Ab-armed ATCs may provide a promising immunotherapy for bladder cancer.
Juan Ma, and
Jing Ge, and
Xin Xue, and
Weigang Xiu, and
Pan Ma, and
Ximing Sun, and
Man Zhang
February 2013,
BMC cancer,
Juan Ma, and
Jing Ge, and
Xin Xue, and
Weigang Xiu, and
Pan Ma, and
Ximing Sun, and
Man Zhang
November 2015,
Current opinion in hematology,
Juan Ma, and
Jing Ge, and
Xin Xue, and
Weigang Xiu, and
Pan Ma, and
Ximing Sun, and
Man Zhang
December 2011,
BioDrugs : clinical immunotherapeutics, biopharmaceuticals and gene therapy,
Juan Ma, and
Jing Ge, and
Xin Xue, and
Weigang Xiu, and
Pan Ma, and
Ximing Sun, and
Man Zhang
June 2013,
Current opinion in chemical biology,
Juan Ma, and
Jing Ge, and
Xin Xue, and
Weigang Xiu, and
Pan Ma, and
Ximing Sun, and
Man Zhang
July 2012,
Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation,
Juan Ma, and
Jing Ge, and
Xin Xue, and
Weigang Xiu, and
Pan Ma, and
Ximing Sun, and
Man Zhang
August 2002,
Biochemical Society transactions,
Juan Ma, and
Jing Ge, and
Xin Xue, and
Weigang Xiu, and
Pan Ma, and
Ximing Sun, and
Man Zhang
April 1998,
Journal of controlled release : official journal of the Controlled Release Society,
Juan Ma, and
Jing Ge, and
Xin Xue, and
Weigang Xiu, and
Pan Ma, and
Ximing Sun, and
Man Zhang
January 2018,
Methods in molecular biology (Clifton, N.J.),
Juan Ma, and
Jing Ge, and
Xin Xue, and
Weigang Xiu, and
Pan Ma, and
Ximing Sun, and
Man Zhang
June 2021,
Oncoimmunology,
Juan Ma, and
Jing Ge, and
Xin Xue, and
Weigang Xiu, and
Pan Ma, and
Ximing Sun, and
Man Zhang
March 2021,
Science (New York, N.Y.),
